Bioenergenix LLC

Reveragen Biopharma, Inc.

Imago Biosciences, Inc.

Vettore, LLC

Centaurus Therapeutics

Pioneura Corporation

The United States of America, As Represented by the Secretary, Department of Health and Human Services

Max-planck-gesellschaft Zur F&#xf6;rderung Der Wissenschaften E. V.

Science Applications International Corporation

Albany Molecular Research, Inc.

Knopp Biosciences, LLC

Cadent Therapeutics, Inc.

Knopp Neurosciences, Inc.

Validus Genetics

Validus Biopharma Inc.

John Michael McCall

Donna Lee Romero

Michael John Clare

Eric Hoffman

Kanneboyina Nagaraju

Hugh Young Rienhoff, Jr

Jesse Damsker

Kenneth Mark Parnell

Robert C Kelly

Cassandra Celatka

John McKearn

Amy E Tapper

Arthur Glenn Romero

Jian-Xie Chen

Jeremy T Blitzer

Harris A Gelbard

Olga V Lapina

Rajendrakumar Reddy Gadikota

Prasad Raje

John Adams Lowe, Iii

Graham Johnson

He Zhao

Eddine Saiah

Birgitte Langer Eriksen

Gregg F Keaney

Martin R Jefson

Heather Tye

Hairuo Peng

Janus Schreiber Larsen

Kai Peter Johnsson

Mark Joseph Tebbe

David John Fairfax

Charlotte Hougaard

Dorte Strøbæk

Elisabeth C A Brot

Holly Atton

Magnus Gustafsson

Mirco Meniconi

Mark Peter Ridgill

Keith Douglas Barnes

Thomas Amos Jacobsen

Xuemei Chen

Matthew Robert Johnson

Mark Anthony Kerry

Adrian Kotey

Zhihua Li

Xiaoming Liao

Betina Biolatto

Toni Chancellor

Jessica Klein

Jill Heemskerk

Katarzyna Irena Gorska

Nathaniel J Monck

Steven Mark Bromidge

Craig Avery

Nagaraju (Raju) Kanneboyina

Nadia Lybøl Von Schoubye

Mark Kerry

Provided herein is a method for treating a monocarboxylate transporter MCT4-mediated disorder in a subject in need thereof. The method comprises the step of administering to the subject a compound of structural Formula I and/or a salt thereof. The treatment of the monocarboxylate transporter MCT4-mediated disorder may inhibit activity of MCT4, or a mutant thereof, sometimes with at least a 100-fold selectivity for MCT4 over MCT1.

MCT4 inhibitors for treating disease

The present invention relates to compounds and methods which may be useful as treatments of neuromuscular diseases such as muscular dystrophy, and as inhibitors of NF-&#x3ba;B for the treatment or prevention of muscular wasting disease, including muscular dystrophy.

Non-hormonal steroid modulators of NF-kB for treatment of disease

Disclosed herein are dihydroceramide desaturase 1 (Des1) inhibitor compounds and compositions, which are useful in the treatment of diseases, such as metabolic, cardiovascular, fibrotic, autoimmune/chronic inflammatory diseases, cystic fibrosis, various cancers, neurodegenerative diseases, lipid storage disorders, and ischemia/reperfusion injury, where inhibition of Des1 is expected to be therapeutic to a patient. Methods of inhibition of Des1 activity in a human or animal subject are also provided.

Inhibitors of dihydroceramide desaturase for treating disease

Disclosed herein are new compounds and compositions and their application as pharmaceuticals for the treatment of diseases. Methods of inhibition of KDM1A, methods of increasing gamma globin gene expression, and methods to induce differentiation of cancer cells in a human or animal subject are also provided for the treatment of diseases such as acute myelogenous leukemia.

KDM1A inhibitors for the treatment of disease

The present invention relates to compounds and methods which may be useful as treatments of diseases.

Non-hormonal steroid modulators of NF-&#x3ba;&#x3b2; for treatment of disease

Provided is a tartrate salt of 3-(1H-indol-5-yl)-5-[4-[(4-methyl-1-piperazinyl)methyl]phenyl]-1H-pyrrolo[2,3-b]pyridine and crystalline forms thereof. Also provided are pharmaceutical compositions comprising a tartrate salt disclosed herein and crystalline forms thereof and a pharmaceutically acceptable excipient, and a method of treating a disease or disorder, such as disease or disorder associated with neuroinflammation, comprising administering to a subject in need thereof, a therapeutically effective amount of an acid addition salt disclosed herein or the pharmaceutical composition of the acid addition salt.

Acid addition salts, compositions, and methods of treating

Provided is an acid addition salt of 3-(1H-indol-5-yl)-5-[4-[(4-methyl-1-piperazinyl)methyl]phenyl]-1H-pyrrolo[2,3-b]pyridine selected from a tartrate salt, a phosphate salt, and a fumarate salt. Also provided are pharmaceutical compositions comprising an acid addition salt disclosed herein and a pharmaceutically acceptable excipient, and a method of treating a disease or disorder, such as disease or disorder associated with neuroinflammation, comprising administering to a subject in need thereof, a therapeutically effective amount of an acid addition salt disclosed herein or the pharmaceutical composition of the acid addition salt.

Acid addition salts, compositions, and methods of treating thereof

Provided is an aqueous oral pharmaceutical suspension composition comprising vamorolone Form I. Also provided are methods for its preparation and its use.

Aqueous oral pharmaceutical suspension compositions

Disclosed herein are new heterocyclic compounds and compositions and their application as pharmaceuticals for the treatment of disease. Methods of inhibiting PAS Kinase (PASK) activity in a human or animal subject are also provided for the treatment of diseases such as diabetes mellitus.

Heterocyclic compounds for the inhibition of PASK

Provided in this disclosure are methods for the synthesis of substituted 2-arylcyclopropylamines and 2-heteroarylcyclopropylamines and related compounds. Also provided are methods for reduction of thioesters to aldehydes, and methods for reductive animation of cyclopropylamines.

Methods and processes for the preparation of KDM1A inhibitors

Disclosed herein are compounds and compositions useful in the treatment of MCT4 mediated diseases, such as proliferative and inflammatory diseases, having the structure of Formula I:  Methods of inhibition MCT4 activity in a human or animal subject are also provided.

Heterocyclic inhibitors of MCT4

Growing community of inventors

Boca Grande, FL, United States of America

John Michael McCall